Recombinant Human B-Lymphocyte Antigen Cd19 (CD19) Protein (His&Myc)

Name: Recombinant Human B-Lymphocyte Antigen Cd19 (CD19) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-11059P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Car-nk targets proteins, Cd19 products, Cluster of differentiation (cd) proteins, Featured cd protein molecules, High-quality recombinant proteins, Recombinant cell therapy targets for car-t research

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human B-Lymphocyte Antigen Cd19 (CD19) Protein (His&Myc) is produced by our Mammalian cell expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P15391
Target Symbol	CD19
Synonyms	CD19; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12; CD antigen CD19
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	N-10His&C-Myc
Target Protein Sequence	PEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWK
Expression Range	20-291aa
Protein Length	Partial
Mol. Weight	35.1
Research Area	Immunology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge.
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Membrane raft; Single-pass type I membrane protein.
Database References	HGNC: 1633 OMIM: 107265 KEGG: hsa:930 STRING: 9606.ENSP00000437940 UniGene: PMID: 28484276 The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS). PMID: 27412504 Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations that display comparatively higher antitumor activity PMID: 28331616 CD19-specific triplebody SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies. PMID: 27825135 The increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion. PMID: 28440417 The preclinical activity, safety and PK profile support clinical investigation of MGD011 (MGD011 is a CD19 x CD3 DART bispecific protein )as a therapeutic candidate for the treatment of B-cell malignancies PMID: 27663593 this study shows that CD19 isoforms enable resistance to adoptive cellular immunotherapy PMID: 28441264 Anti-CD19-chimeric antigen receptors T cells synergistically exerted collaborative cytotoxicity against primary double-hit lymphoma cells with anti-CD38-chimeric antigen receptors T cells. PMID: 28595585 Two infants with relapsed, refractory B-cell acute lymphoblastic leukemia went into complete remission after being treated with CD19-targeting CAR T cells derived from an unmatched donor PMID: 28193774 These data provide proof-of-principle for the view that newly generated Ab-secreting cells can acquire a mature plasma cell phenotype that is accompanied by loss of CD19 expression at an early stage of differentiation and that aging is not an obligate requirement for a CD19(neg) state to be established. PMID: 28490574 Results indicate the strong efficacy of FLAG-tagged CD19 CAR-T cells in solid and hematological cancer models. PMID: 28410137 The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy. PMID: 27748274 The frequencies of CD19+CD24hiCD38hi B-regulatory lymphocyte were significantly increased in children with beta-thalassemia. PMID: 26852663 a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma. PMID: 25739938 CD19 is required for TLR9-induced B-cell activation. Hence CD19/PI3K/AKT/BTK is an essential axis integrating BCRs and TLR9 signaling in human B cells. PMID: 26478008 High anti-EBV IgG levels in Crohn's disease are associated with 5-aminosalicylic acid treatment, tonsillectomy, and decrease of CD19(+) cells. PMID: 25914477 We propose that CD81 enables the maturation of CD19 and its trafficking to the membrane by regulating the exit of CD19 from the ER to the pre-Golgi compartment PMID: 25739915 we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR(+) T cells on AaPCs PMID: 25591810 We demonstrate that this motif plays a role in the maturation and recycling of CD19 but in a CD81-independent manner. PMID: 26111452 Studies indicate that anti-CD19 and anti-CD33 bispecific antibodies showed anticancer activity. PMID: 25883042 The synaptic recruitment of lipid rafts is dependent on CD19-PI3K module and cytoskeleton remodeling molecules. PMID: 25979433 gene deficiency results in severe lung disease in French patient PMID: 24684239 propose a multilayer model of plasma cell (PC) memory in which CD19(+) and CD19(-) PC represent dynamic and static components, respectively, permitting both adaptation and stability of humoral immune protection PMID: 25573986 Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. PMID: 24828435 Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. PMID: 24418477 A lower primary CD24(hi) CD27(+) CD19(+) B cells may be an immunologic aspect of new-onset SLE that may be a useful tool to evaluate lupus activity and monitor the response to therapy. PMID: 24286662 higher percentage of CD19+ cells in patients with acute appendicitis; decreases after appendectomy PMID: 24375063 CD20 and CD19 targeting vectors induce activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction. PMID: 24244415 Latently infected cells from patients with multiple sclerosis, treated with natalizumab, initiate differentiation to CD19+ cells that favor growth of JC polyomavirus. PMID: 24664166 This inhibitory function of FcgammaRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell immunological synapse may help explain the hyper-reactive features of systemic lupus erythematosus PMID: 24790152 Considering that the CD19 complex regulates the events following antigen stimulation, the change in CD19 complex detected in transient hypogammaglobulinemia of infancy may be related to insufficiency of antibody production. PMID: 22820757 CD19 emerged as a powerful predictor of event-free and overall survival in CNS diffuse large B-cell lymphomas and Burkitt lymphomas PMID: 24501214 these data demonstrate that CD19 and CD32b differentially inhibit B cell expansion and plasma cell differentiation, depending on the nature of the activating stimuli, when engaged with monospecific Abs. PMID: 24442430 CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. PMID: 23193950 CD19 is expressed very early in B-cell development and is a good target for antibody therapy in lymphoblastic leukemia. PMID: 23277329 The resulting CD19(high)/CD19(low) B-cell ratio increased markedly in the milk-tolerant group. PMID: 22563781 Use of c-Myc transgenic mice deficient in CD19 expression leads to identification of a c-Myc:CD19 regulatory loop that positively influences B cell transformation and lymphoma progression. PMID: 22826319 Results obtained through a large cohort of European caucasian patients with systemic sclerosis do not support the contribution of CD19, CD20, CD22, CD24 variants to the genetic susceptibility. PMID: 21961844 Data indicate that among MDS cases, CD15+ and CD19+ cell TLs were positively correlated, and PBL TL was was not associated with hTERT genotype. PMID: 21635204 Studies showed the qualitative and quantitative expression of four target surface antigens, CD19, CD20, CD22, and CD33, for which MoAbs are currently available for clinical use, in ALL. PMID: 21348573 Data show that CD45+CD19- MCL-ICs play a role in the drug resistance of MCL, and this drug resistance was largely due to quiescent properties with enriched ABC transporters. PMID: 21599592 A missense mutation of CD19 in the conserved tryptophan 41 in immunoglobulin superfamily domain resulted in antibody deficiency. PMID: 21330302 Data suggest that CD19 and CD33 are present on the surface of the leukemic cell lines such that they can be connected by a single sctb molecule. PMID: 21081841 CD23 and CD19 are important factors that associated with serum total IgE in the pathogenesis of allergic rhinitis. PMID: 20359104 binding sites for CD19 and CD16 have a role in antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells PMID: 21339041 Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. PMID: 20445561 Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus. PMID: 20726320 The CD27(+) B-cell population was found to highly express CXCR3 in chronic hepatitis C (CHC), thus suggesting that the CD27(+) B-cell population was recruited from peripheral blood to the inflammatory site of the liver of CHC. PMID: 20377416 Aberrant expression of CD19 in acute myeloblastic leukemia with t(8;21) involves a poised chromatin structure and PAX5. PMID: 20208555 Studies indicate taht B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. PMID: 20164433

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.